Vertex
Top Ten most popular articles on Pharmafile.com this week!
February 1, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, England, NHS, Purdue, Vertex, insys, israel, oncology, pharma, top 10
Scandal dominated this week’s news after Sunrise Lee, a stripper turned Insys sales rep was alleged to have given a …
Vertex ousts COO Ian Smith over ‘personal behaviour’
January 24, 2019Business Services Ian Smith, Jobs, Vertex, executives
Boston-based firm Vertex Pharmaceuticals has fired Chief Operating Officer (COO) and interim Chief Financial Officer (CFO) Ian Smith. Smith’s termination, …
Vertex’s Orkambi can be used in even younger cystic fibrosis patients, says European Commission
January 22, 2019Manufacturing and Production, Sales and Marketing Orkambi, Vertex, cystic fibrosis, pharma
Vertex has announced that the European Commission has decided to approve a label extension in the region for Orkambi (lumacaftor/ivacaftor) …
UK Health Secretary Matt Hancock rallies against ‘rip off’ pharma companies
September 11, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, Matt Hancock, NICE, Vertex, pharma, pricing
British Health Secretary Matt Hancock has said that pharmaceutical companies are trying to “rip off taxpayers” and that big business …
Working Life: Vertex Pharma’s Simon Lem, VP, Regional General Manager of North Europe
June 25, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Vertex, Vertex pahrma, Working Life, feature, pharma
Pharmafocus caught up with Vertex Pharma’s Simon Lem to discuss his journey throughout the industry and the importance of the …
UK Ministers call on Vertex to speed up price negotiations
April 23, 2018Sales and Marketing NHS, NICE, Orkambi, UK government, Vertex, biotech, drugs, pharma, pharmaceutical
After a parliamentary debate in the House of Commons regarding making Orkambi available to patients with cystic fibrosis (CF), MPs …
Transforming cystic fibrosis treatment
April 5, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Vertex, biotech, cystic fibrosis, drugs, pharma, pharmaceutical
Fred van Goor, Principle Research Fellow at Vertex Pharmaceuticals, discusses his history of work in cystic fibrosis and how the …
Top Ten most popular articles on Pharmafile.com this week
March 23, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Canada, Celgene, Lundbeck, Marijuana, Novartis, Roche, Vertex, brexit, cannabis, multiple sclerosis, neuroscience, pharma
As me move startlingly quickly towards Easter, it’s time for another Top Ten rundown. This week, Celgene surprised the industry …
Vertex “astonished” by NHS England’s response to CF drug
March 20, 2018Manufacturing and Production, Sales and Marketing Vertex, biotech, cystic fibrosis, drugs, pharma, pharmaceutical
Vertex has been battling to have its treatment, Orkambi, approved in the UK since 2016, when it was first rejected …
Vertex gets approval for combo-therapy in cystic fibrosis
February 13, 2018Manufacturing and Production, Sales and Marketing Vertex, biotech, cystic fibrosis, drugs, pharma, pharmaceutical
All eyes are on Vertex’s two Phase 3 trials into a triple therapy for cystic fibrosis (CF), in the meantime, …
Merck in $230 million swoop for Vertex cancer programmes
January 16, 2017Sales and Marketing Vertex
Merck has completed a deal with Boston-based biotech firm Vertex Pharmaceuticals for the rights to four cancer programmes worth $230 …
Vertex stumbles in Phase III cystic fibrosis trials
August 16, 2016Manufacturing and Production, Research and Development Vertex, cystic fibrosis, phase III
Vertex Pharmaceuticals has provided an update on its ongoing Phase III trials investigating VX-661 in combination with Kalydeco (ivacaftor) in …
Orkambi deemed not suitable for NHS use
July 27, 2016Manufacturing and Production, Research and Development Orkambi, Vertex, Vertex Pharma, cystic fibrosis
The National Institute for Health and Care Excellence (NICE) has issued its recommendation that the cystic fibrosis drug Orkambi (lumacaftor/ivacaftor) …
NICE draft guidance says ‘no’ to cystic fibrosis drug Orkambi
March 23, 2016Research and Development, Sales and Marketing NICE, Orkambi, Vertex, cystic fibrosis
NICE has issued draft guidance not recommending Vertex’s Orkambi (lumacaftor/ivacaftor) for use on the National Health Service (NHS) in England …
Vertex’s cystic fibrosis drug gets FDA approval
July 3, 2015Research and Development, Sales and Marketing FDA, Orkambi, Vertex, cystic fibrosis, gene therapy
Vertex Pharmaceuticals cystic-fibrosis drug Orkambi, which could treat as many as 8,500 patients in the US, has been approved by …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
